A pancreatic cancer doctor
@DanZhaoMD
Followers
454
Following
2K
Media
126
Statuses
704
Asst. Professor of GI Medical Oncology, @MDAndersonNews, specializing in #PancreaticCancer. Views are my own. Research: #Immunology, #ClinicalTrials, #KRAS
Houston, TX
Joined January 2020
Preprint from @HaoqiangY & @wantong_yao labs @MDAndersonNews KRAS inhibition activates an actionable CD24 do-not-eat-me signal in #PancreaticCancer
https://t.co/Hg6iFvVodu A new mechanism of resistance to KRAS inhibitors + an autochthonous model of the KRAS G12C allelic variant
0
13
58
A series from @Huaminwang6 & colleagues on an exceedingly rare and dreaded event in #PancreaticCancer - brain metastases. These lesions tend to have a unique papillary architecture (likely a result of the unique TME) & occur late in the natural history. https://t.co/zuVEzBTL5T
0
3
16
ha! here is something fun and totally random I've been pondering: as Oliver Sacks has beautifully written - "what is the space between two snowflakes?" Language can describe all the things, stuff, and people in intricate details. But what about the 'space', the 'nothingness' in
Fei-Fei Li (@drfeifei) on limitations of LLMs. "There's no language out there in nature. You don't go out in nature and there's words written in the sky for you.. There is a 3D world that follows laws of physics." Language is purely generated signal. https://t.co/FOomRpGTad
107
236
2K
Two important randomized trials in #PancreaticCancer published: 1st PASS-01 in metastatic cancer comparing FOLFIRINOX to Gem/Abraxane (@JCO_ASCO) 2nd PREOPANC-2 in resectable/borderline resectable cancer comparing neoadjuvant FFX versus Gem/CRT (@TheLancetOncol) @OncoAlert ā¬ļø
1
49
121
Revolution Medicines Daraxonrasib data in first line metastatic #PancreaticCancer - monotherapy & combination with Gemcitabine nab-paclitaxel. Even monotherapy ORRs and DCRs are impressive! Do you need the chemo? Grade 3 AEs go from 35% to 58%. RASOLUTE 303 will answer.
8
56
195
Above everything, @DRCamidge is generous. He has touched the lives of countless patients - and oncologists, around the world. His wisdom and humor come through in his podcast, "How This is Building Me" which I highly recommend: https://t.co/yNotn0zh3y
onclive.com
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
0
8
39
Science, music, and a little bit of fun. šø In the latest episode of The ImmunoVerse, Dr. Tom Gajewski and I dive into how researchers are turning ācoldā tumors āhotā to respond to immunotherapy ā and share a story about forming a @sitcancer band called The CheckPoints. Listen
3
8
27
One of the biggest influences on my career is Dr. Ross Camidge - a mentor and friend, an intellectual giant in the field of lung cancer who was diagnosed with this unforgiving disease himself. We are all at risk - and must all work to move the field. https://t.co/GHuaFBUoBm
news.cuanschutz.edu
D. Ross Camidge, MD, PhD, has spent his career fighting lung cancer. In 2022, that fight turned personal when he received a diagnosis of his own.
10
57
234
Pancreatic cancer incidence is increasing, though the reasons are unclear. More oncologists and researchers are needed to support patients with this disease.
Precise risks are unknown. The LNP (lipid nanoparticle) that encapsulates the vaccines take the modified RNA, DNA fragments and any residual plasmid from manufacturing into the nucleus. Fragments can insert in the genome and the plasmid can turn the cell into a spike protein
1
4
10
I have read the paper and find it to be clear, factual, informative and well-written. There is clear evidence of residual DNA fragments, plasmid DNA in both Pfizer & Moderna vaccines along with SV40 promoter-enhancer-ORI sequences in Pfizer lots. Association with VAERS reported.
Quantification of residual plasmid DNA and SV40 promoter-enhancer sequences in Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada https://t.co/zfHjCMtxAi
47
656
2K
David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87 - The New York Times
nytimes.com
He was only 37 when he made a discovery that challenged the existing tenets of biology and led to an understanding of retroviruses and viruses, including H.I.V.
0
0
1
Shared some insights on #ctDNAās power to guide clinical decisions in GI cancersāenabling precision treatment, improved surveillance, and earlier intervention for colorectal cancer patients. Excited by the fieldās rapid progress towards personalized care! https://t.co/dSznBGCkSM
4
6
39
In a new Perspective, Kerstin N. Vokinger, MD, JD, PhD, Guanqiao Li, MD, and Olivier J. Wouters, PhD (@ojwouters), write that China has recently emerged as an important player in new drug development ā a field traditionally dominated by the United States and Europe. This shift
0
8
26
VERY proud of our @MDAndersonNews team's work now online @Cancer_Cell for BRAF+EGFR+PD1 blockade in MSS, BRAF V600E mCRC. ORR 50%, mPFS >7 mos w/encorafenib + cetuximab + nivolumab š§µto expand IO benefit+liquid biopsy utility in high-risk MSS CRC pts https://t.co/PvL2SdFG3g
12
27
108
Targeting the YAP-SDC1 axis overcomes resistance to KRASi in GI cancers by blocking SDC1-driven macropinocytosis and RTK activation, offering a promising strategy for KRASi resistance. @wantong_yaoĀ @HaoqiangY @CellRepMed #crcsm To the clinic! https://t.co/CwYZwvDXci
3
14
65
FDA grants accelerated approval to dordaviprone/ONC201 for diffuse midline glioma | FDA I am glad to see the approval and grateful to be part of Dr. Andrew S. Chiās team working on ONC201 at Mass General Cancer Center (2012-2014).
fda.gov
On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone.
0
0
2
Episode 2 of #TheImmunoVerse is out! I sat down with Dr. Philip Greenberg of @fredhutch to discuss the evolution of T cell therapy and why itās vital that scientists share their discoveries and spark excitement beyond the lab. When the public understands science, progress
1
5
24
Honored to have esteemed colleague Elizabeth Jaffee, MD (@DrLizJaffee) of @HopkinsMedicine on the latest episode of #TheImmunoVerse podcast, out today! In this episode, we discuss the decades-long effort to target KRAS, recent breakthroughs in pancreatic cancer research and
2
8
31